1
|
Juliusson G, Antunovic P, Derolf A, et al:
Age and acute myeloid leukemia: real world data on decision to
treat and outcomes from the Swedish Acute Leukemia Registry. Blood.
113:4179–4187. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Vey N: Targeting age-related changes in
the biology of acute myeloid leukemia: is the patient seeing the
progress? Interdiscip Top Gerontol. 38:73–84. 2013.PubMed/NCBI
|
3
|
Yanada M, Ohtake S, Miyawaki S, et al:
Japan Adult Leukemia Study Group: The demarcation between younger
and older acute myeloid leukemia patients: a pooled analysis of 3
prospective studies. Cancer. 119:3326–3333. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shimoni A, Kroger N, Zabelina T, et al:
Hematopoietic stem-cell transplantation from unrelated donors in
elderly patients (age >55 years) with hematologic malignancies:
older age is no longer a contraindication when using reduced
intensity conditioning. Leukemia. 19:7–12. 2005.PubMed/NCBI
|
5
|
Lazarevic V, Horstedt AS, Johansson B, et
al: Incidence and prognostic significance of karyotypic subgroups
in older patients with acute myeloid leukemia: the Swedish
population-based experience. Blood Cancer J. 4:e1882014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Leith CP, Kopecky KJ, Chen IM, et al:
Frequency and clinical significance of the expression of the
multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in
acute myeloid leukemia: a Southwest Oncology Group Study. Blood.
94:1086–1099. 1999.PubMed/NCBI
|
7
|
Leone G, Mele L, Pulsoni A, Equitani F and
Pagano L: The incidence of secondary leukemias. Haematologica.
84:937–945. 1999.PubMed/NCBI
|
8
|
Ostgård LS, Kjeldsen E, Holm MS, et al:
Reasons for treating secondary AML as de novo AML. Eur J Haematol.
85:217–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Guo M, Hu KX, Yu CL, et al: Infusion of
HLA-mismatched peripheral blood stem cells improves the outcome of
chemotherapy for acute myeloid leukemia in elderly patients. Blood.
117:936–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Guo M, Hu KX, Liu GX, et al:
HLA-mismatched stem-cell microtransplantation as postremission
therapy for acute myeloid leukemia: long-term follow-up. J Clin
Oncol. 30:4084–4090. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chen YS, Kong XJ, Zhang XH and Yin XL:
Treatment of acute mixed-cell leukemia with autologous
hematopoietic SCT followed by allogeneic hematopoietic stem cell
micro-transplantation. Bone Marrow Transplant. 49:984–985. 2014.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Appelbaum FR, Gundacker H, Head DR, et al:
Age and acute myeloid leukemia. Blood. 107:3481–3485. 2006.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Al-Seraihy AS, Owaidah TM, Ayas M, El-Solh
H, Al-Mahr M, Al-Ahmari A and Belgaumi AF: Clinical characteristics
and outcome of children with biphenotypic acute leukemia.
Haematologica. 94:1682–1690. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Miyawaki S, Sakamaki H, Ohtake S, et al:
Japan Adult Leukemia Study Group AML 97 Study: A randomized,
postremission comparison of four courses of standard-dose
consolidation therapy without maintenance therapy versus three
courses of standard-dose consolidation with maintenance therapy in
adults with acute myeloid leukemia: the Japan Adult Leukemia Study
Group AML 97 Study. Cancer. 104:2726–2734. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hengeveld M, Suciu S, Karrasch M, et al:
Intensive consolidation therapy compared with standard
consolidation and maintenance therapy for adults with acute myeloid
leukaemia aged between 46 and 60 years: final results of the
randomized phase III study (AML 8B) of the European Organization
for Research and Treatment of Cancer (EORTC) and the Gruppo
Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA)
Leukemia Cooperative Groups. Ann Hematol. 91:825–835. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Büchner T, Hiddemann W, Berdel WE, et al:
German AML Cooperative Group: 6-Thioguanine, cytarabine and
daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM)
for induction, TAD for consolidation and either prolonged
maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of
intensive consolidation by sequential HAM in adult patients at all
ages with de novo acute myeloid leukemia (AML): a randomized trial
of the German AML Cooperative Group. J Clin Oncol. 21:4496–4504.
2003.PubMed/NCBI
|
17
|
Ferrero D, Crisà E, Marmont F, et al:
Survival improvement of poor-prognosis AML/MDS patients by
maintenance treatment with low-dose chemotherapy and
differentiating agents. Ann Hematol. 93:1391–1400. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lö Wenberg B, Suciu S, Archimbaud E, et
al: Mitoxantrone versus daunorubicin in induction-consolidation
chemotherapy - the value of low-dose cytarabine for maintenance of
remission, and an assessment of prognostic factors in acute myeloid
leukemia in the elderly: final report. European Organization for
the Research and Treatment of Cancer and the Dutch-Belgian
Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 16:872–881.
1998.PubMed/NCBI
|
19
|
Polák J, Hájková H, Maalaufová-Soukupová
J, et al: Estimation of molecular upper remission limit for
monitoring minimal residual disease in peripheral blood of acute
myeloid leukemia patients by WT1 expression. Exp Ther Med.
3:129–133. 2012.PubMed/NCBI
|